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Sarah Ratzel1 and Sara B. Cullinan2Exploring the Structural-Variation Landscape in
Esophageal Cancer
Cheng et al., p. 256
With the advent, and reduction in cost, of next-generation
sequencing, large-scale studies of diverse cancer types have
yielded unparalleled insights into the genetic causes of can-
cer. The hope is that these sequencing-based studies will
inform the development and implementation of targeted
therapeutics. Although many studies have focused on the
identification of exonic single-nucleotide variants (SNVs),
the presence of structural variation in cancer genomes is
well documented and is also thought to contribute to
both tumorigenesis and cancer progression. In this issue,
Cheng et al. utilize whole-genome sequencing (WGS) to
identify and catalog structural variation present in esopha-
geal squamous cell carcinoma (ESCC). Through their efforts
to understand the nature of these genomic changes, the
authors uncovered a diversity of mutational processes—
including aberrant NHEJ, chromothripsis, and kataegis—
that drive recurrent structural variation. Future studies
aimed at exploring the constellation of SNVs that are pre-
sent in noncoding regions of the genome, changes to the
transcriptome, and the presence of early biomarkers will
all play a role in achieving the goal of implementing a pre-
cision-medicine approach in the treatment of ESCC.Huntington Disease Duration Is Independent of
Repeat Length
Keum et al., p. 287
Huntington disease (HD) is caused by an expanded CAG
repeat in HTT. Characterized repeat lengths vary, but it is
generally agreed that longer repeat lengths are more path-
ogenic. For example, previous work has demonstrated that
clinical onset and age at death are determined by the
length of the expanded CAG repeat tract. In this issue,
Keum et al. take a closer look at the relationship between
the repeat length and clinical characteristics of HD. The au-
thors find that disease duration—the time from diagnosis
to death—was independent of the length of the expanded
CAG repeat in cohorts ascertained across different studies.
However, the disease duration did vary in cases of extreme
juvenile-onset HD, and men had a slightly shorter disease
duration than did females. A recent study identified amod-
ifier of age of onset and age of death in individuals who1Scientific Editor, AJHG; 2Deputy Editor, AJHG
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The Americharbor expanded CAG repeats. This SNP, however, did
not appear to affect disease duration. This work from
Keum et al. supports a model in which age of onset is
driven by the CAG repeat length, but once reaching a crit-
ical level, the disease progresses at a similar rate in most
affected individuals. The mechanism and identity of tis-
sues crucial for this decline remain unclear, but their dis-
covery holds promise for future therapeutic developments.Extreme Gene Expression Helps to Identify Rare
Promoter Variants of Interest
Zhao et al., p. 299
As increasing numbers of studies attempt to analyze non-
coding sequence, researchers are examining the role of
variation located outside of exons more extensively. Varia-
tion within promoters is ripe for exploration because these
variants are likely to have an impact on gene expression. In
this issue, Zhao et al. identified an enrichment of rare var-
iants within the promoters of genes that display increased
and decreased expression levels in healthy individuals. It
appears that this signal could be driven largely by variants
found in DNase-hypersensitive sites and in transcription-
factor-binding sites and that a higher burden of rare vari-
ants is found in genes lacking a gene-disease association,
reflecting reduced purifying selection for genes associated
with disease. This result holds true when the analysis is
conducted with rare haplotypes instead of single, rare var-
iants. An intriguing source of rare haplotypes is introgres-
sion from archaic human populations; however, in this
work Neanderthal haplotypes did not appear to play a
notable role in differential gene expression. To validate
their statistical analysis, the authors modified four sites
with large effect sizes by using CRISPR/Cas9 technology,
and the resulting small deletions appeared to affect tran-
scription to varying extents. Although this work was per-
formed in blood, the authors’ approach could be applied
to other tissues to identify rare variants that influence
expression in a tissue-specific manner and might be worth
further evaluation.Disrupted Golgi Homeostasis
Jansen et al., p. 310 and p. 322
The Golgi complex serves as a nexus for the secretory,
lysosomal, and endocytic pathways. A specialized groupy of Human Genetics. All rights reserved.
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of glycosylation enzymes resides within the Golgi, and
the malfunction of these enzymes renders proteins
incompletely processed and unfit for proper secretion.
Recent work has defined a subset of congenital disorders
of glycosylation (CDGs) as stemming from altered ho-
meostasis within the Golgi. In this issue, Jansen et al.
leverage biochemical and cell biological knowledge
from yeast studies to describe two human genetic disor-
ders caused by disruptions to Golgi homeostasis. In
their first study, the authors identify pathogenic
CCDC115 variants in five families whose members
display similar storage-disease-like phenotypes and
share a biochemical profile of abnormal glycosylation
profiles. The authors’ identification of pathogenic
TMEM199 mutations was somewhat less straightfor-
ward. They performed a prioritized scan of unsolved
CDG cases by searching for variants in orthologs of
yeast genes whose products are integral to proper Golgi
function. Their search uncovered TMEM199 variants
that had escaped previous detection as a result of poor
coverage of this locus. TMEM199 and CCDC115 encode
assembly factors of the V-ATPase, the proton pump that
acidifies the secretory pathway. These findings suggest a
role for comparative genomics in future efforts aimed at
identifying causes of disorders with a defined biochem-
ical profile.226 The American Journal of Human Genetics 98, 225–226, FebruaryMitotic Recombination in CDGs
Kane et al., p. 339
Congenital disorders of glycosylation (CDGs) are caused by
defects in enzymes that are required for protein glycosyla-
tion. Most CDG-affected individuals harbor compound
heterozyogous mutations, and the penetrance and pheno-
typic expressivity varywidely across individuals withmuta-
tions in the samegene. In this study, Kane et al. used various
sequencing approaches to identify non-parental genotypes
in siblings who hadMOGSmutations andwho experienced
much longer lifespans than other affected individuals.
CDG-affected individuals with defects in other genes,
including PMM2, MPI, ALG3, ALG12, DPAGT1, and ALG1,
also harbored non-parental alleles, suggesting that this
mechanism is generalizable to CDGs. One explanation
might be thatmitotic recombination allows a certain popu-
lationof somatic cells to lose themutant alleles and that this
might lead to improved enzyme function and a selective
growth advantage. Such a mechanism has been observed
in other genetic disorders, including some hematological
diseases. Although the extent to whichmitotic recombina-
tion alters the phenotypic presentation of disorders charac-
terizedbyanenrichmentof compoundheterozygousmuta-
tions is currently unknown, it might explain reduced
phenotypic expressivity and severity in certain individuals.4, 2016
